Project Grant R01CA286122
Award Date
7/17/24
Completion Date
6/30/29
Dollars Obligated
$577K
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
Michigan, USA
Similar Awards
The National Cancer Institute (NCI) awarded a Project Grant (CFDA 93.395 - Cancer Treatment Research) to Ampedrna Biosciences LLC in the amount of $398,823 to develop a highly immunogenic mini-circular RNA (mcrRNA) therapeutic cancer vaccine for human papillomavirus (HPV)-related cancers. The goal is to create an off-the-shelf or personalized vaccine that can elicit robust and durable T cell responses to target HPV E6 and E7 antigens, which are known to drive HPV-induced cancers. The proposed...
This Project Grant award from the National Cancer Institute (CFDA 93.396 Cancer Biology Research) provides $628,499 to the University of California, Los Angeles to develop innovative mRNA vaccines to enhance the efficacy of T-cell transfer therapies against solid tumors, with a focus on pancreatic ductal adenocarcinoma. The research framework includes mechanistic studies to optimize mRNA-encoded antigen and adjuvant properties, evaluate the new vaccines in humanized immune system mouse models,...
This Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) provides $630,781 to The Johns Hopkins University to develop engineered lipid nanoparticle (LNP) formulations and mRNA LNP-loaded microgels to program Th1/Th2 immune responses for cancer immunotherapy. The key objectives are to: (1) develop mRNA LNP formulations capable of eliciting dual or biased Th1 and/or Th2 immune responses; (2) engineer mRNA LNP-loaded microgels as an immunostimulatory niche...
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $380,337 to the University of Washington to develop machine learning approaches and massively parallel reporter assays (MPRAs) to optimize mRNA sequences for cancer immunotherapy. The goal is to build predictive models that relate mRNA sequence to stability and translation, and then use these models to generate synthetic 5' and 3' untranslated regions (UTRs) and coding sequences (CDS)...
This $379,981 Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) aims to develop a localized cancer immunotherapy using particle-anchored cytokines for prolonged intratumoral retention. The primary objectives are to: (I) develop liposome-anchored cytokines with extended tumor retention and minimal systemic leakage, and (II) elucidate the mechanisms by which particle-anchored cytokines elicit durable anti-tumor immunity to improve efficacy in poorly...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) for $1,419,108 will support research to advance the understanding of how a novel neoadjuvant therapy impacts the immune system in patients with solid tumors, using refractory melanoma as a model. The research, led by Emory University, will use surgical tissue specimens from a clinical trial to gain insights into how blocking the SEMA4D signaling pathway in combination with immune checkpoint...
This $131,220 Project Grant from the National Cancer Institute, part of the Department of Health and Human Services, will support cancer vaccine research under the Cancer Research Manpower federal grant program (CFDA 93.398). The grant recipient, Stanford University, will develop a new approach to cancer vaccination that directly reprograms cancer cells into antigen presenting cells (APCs) through mRNA-enabled cell reprogramming. Researchers aim to overcome barriers to current vaccination...
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) to Dartmouth-Hitchcock Clinic is focused on understanding the role of melanocyte PD-L1 expression in modulating the immune response to UV-induced melanoma. The $635,946 award, with a performance period from July 2024 to June 2029, will support research using an autochthonous mouse melanoma model to investigate how UV radiation-induced interferon-I signaling and tumor inflammatory memory...
This $1,024,967 federal Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) supports the development of CM-HZ01, a novel non-alpha-IL2 therapeutic for the treatment of metastatic melanoma. The funding will advance CM-HZ01, an IL-2 super-agonist, through investigational new drug (IND) studies for this aggressive form of skin cancer, which has limited effective treatment options. The project aims to leverage CM-HZ01's ability to preferentially promote CD8...
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $442,236 to the University of Alabama at Birmingham to investigate the role of the YTHDF1 RNA-binding protein in driving melanoma metastasis. The research aims to determine how YTHDF1 promotes melanoma cell anoikis resistance and suppresses natural killer cell-mediated anti-tumor immunity, with a focus on the downstream mediators IMPDH1 and the TRKB/BDNF pathway. The project will...